Prescription Required
Formulation: Extended Release Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Extended Release Tablet
(Generic Alternative)
Select the prescribed dosage
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Ampyra contains the active ingredient dalfampridine. It is a prescription extended-release medication used to improve walking in adults with multiple sclerosis, also known as MS.
Clinical studies showed that some patients taking Ampyra were able to walk faster. However, not everyone responds to treatment.
Multiple sclerosis is a long-term condition that affects the brain, spinal cord, and optic nerves.
Healthy nerves are protected by a fatty covering called myelin. Myelin helps electrical signals move quickly and efficiently between the brain and the rest of the body.
In people with MS, the immune system damages myelin and the nerve fibers beneath it. This damage may slow, weaken, or interrupt nerve signals.
Difficulty walking is a common problem for people with MS.
Walking may be affected by:
These problems may make it harder to walk quickly, climb stairs, maintain balance, or complete everyday activities.
Ampyra belongs to a class of medications called potassium channel blockers.
When myelin is damaged, potassium may escape through channels in the nerve fibers. This can interfere with the electrical signals travelling along the nerves.
Dalfampridine blocks some of these potassium channels. This may help electrical signals travel more effectively through damaged nerves.
Improved nerve signaling may help the muscles involved in walking work more efficiently.
Ampyra is specifically approved to help improve walking speed in adults with MS.
Some people who respond to treatment may notice that they can:
The amount of improvement varies. Ampyra does not guarantee that walking will return to normal.
Ampyra is approved to improve walking. It is not specifically approved to treat every symptom of MS.
It may not directly improve:
A healthcare provider may prescribe other treatments for these symptoms.
Ampyra is considered a symptomatic treatment.
This means it may improve a specific problem caused by MS, such as reduced walking speed. It does not treat the underlying immune-system activity that causes MS.
Ampyra may be used alongside disease-modifying MS medications when appropriate.
Disease-modifying therapies are used to reduce MS disease activity, lower the number of relapses, and help slow the development of new damage.
Ampyra does not replace these treatments. It has not been shown to prevent relapses or stop MS from progressing.
Continue taking your disease-modifying medication unless your healthcare provider tells you to change it.
A healthcare provider may assess your walking before and after starting Ampyra.
This may include checking:
A timed walking test may be used to determine whether treatment is helping.
Some patients experience a meaningful improvement in walking, while others notice little or no benefit.
Your healthcare provider may continue treatment only if Ampyra provides a useful improvement in your mobility or daily function.
Do not take extra medication if you do not notice an immediate benefit. Higher doses increase the risk of seizures and do not provide greater walking improvement.
Ampyra is supplied as an extended-release tablet.
The tablet releases dalfampridine gradually over several hours. This helps maintain more consistent medication levels in the body.
The extended-release tablet must be swallowed whole. Crushing, chewing, splitting, or dissolving it may release too much medication at once and increase the risk of serious side effects.
The kidneys remove dalfampridine from the body.
If kidney function is reduced, the medication may build up in the bloodstream. Higher medication levels can increase the risk of seizures.
Ampyra must not be used in people with moderate or severe kidney impairment. Kidney function should be checked before treatment and monitored when appropriate.
Ampyra can cause seizures, even in some people who have never had one before.
The risk increases when medication levels become too high. Ampyra should not be used by anyone with a history of seizures.
Stop taking Ampyra and seek immediate medical care if a seizure occurs. Treatment should not be restarted unless a specialist provides different instructions.
Ampyra may be one part of a broader plan to improve mobility.
Other parts of the plan may include:
Medication may work best when combined with rehabilitation and practical mobility support.
A healthcare provider will decide whether Ampyra is appropriate based on:
Use Ampyra exactly as prescribed. Do not increase the dose, take doses too close together, or combine it with another dalfampridine or 4-aminopyridine product.
Ampyra may help improve walking, but it does not cure multiple sclerosis.
Continue attending regular appointments so your healthcare provider can assess your mobility, kidney function, side effects, and overall MS treatment plan.
Contact your healthcare provider if your walking becomes worse, you experience frequent falls, or you do not notice a meaningful benefit from treatment.
Take Ampyra exactly as prescribed by your healthcare provider.
The usual dose is one 10 mg extended-release tablet taken twice daily. Take the two doses approximately 12 hours apart, such as once in the morning and once in the evening.
Do not take more than two tablets within 24 hours.
Ampyra may be taken with or without food.
Choose a routine that is easy to follow and take each dose at approximately the same time every day. Keeping a regular schedule helps prevent doses from being taken too close together.
Swallow the tablet whole with water.
Do not:
Ampyra is an extended-release medication. The tablet is designed to release dalfampridine gradually over several hours.
Breaking or crushing it may release too much medication at once. This can produce dangerously high medication levels and increase the risk of seizures.
Tell your healthcare provider if you cannot swallow the tablet whole.
Do not crush or alter it to make swallowing easier. Your healthcare provider can assess whether Ampyra remains a suitable treatment or discuss other ways to manage your walking difficulties.
The recommended dose is one 10 mg tablet every 12 hours.
Taking more than the recommended amount has not been shown to provide greater improvement in walking. Higher doses can significantly increase the risk of seizures and other serious side effects.
The dose should not be increased because:
Contact your healthcare provider if you do not notice a meaningful benefit.
Keep approximately 12 hours between doses.
Do not take the doses too close together, even if this seems more convenient. Taking a second tablet too soon can cause dalfampridine to build up in the body.
A regular morning and evening schedule can help you maintain the correct interval.
If you miss a dose, skip it.
Take your next tablet at the regular scheduled time. Do not take a late dose if doing so would place it too close to your next one.
Never take:
The kidneys remove dalfampridine from the body.
If kidney function is reduced, the medication can build up in the blood and increase the risk of seizures. Your healthcare provider should check your kidney function before treatment and may repeat this assessment during treatment.
Tell your healthcare provider if you have kidney disease or reduced kidney function.
Ampyra should not be used in people with moderate or severe kidney impairment.
Ampyra can cause seizures, even in some people who have never had a seizure before.
The risk becomes higher if:
Do not use Ampyra if you have a history of seizures unless a specialist has clearly determined otherwise.
Stop taking Ampyra and seek immediate medical care if a seizure occurs. The medication is generally not restarted after a seizure.
Do not take Ampyra with another medication containing dalfampridine, fampridine, or 4-aminopyridine.
These products contain the same or a closely related active ingredient. Combining them may cause an overdose and increase the risk of seizures.
Tell your healthcare provider and pharmacist about all prescription medications, compounded products, vitamins, and supplements you use.
Some people may notice improved walking after beginning treatment, while others may not experience a meaningful benefit.
Your healthcare provider may assess:
Continue treatment only as directed. Do not increase the dose if improvement is limited.
Regular follow-up helps your healthcare provider determine whether Ampyra is working safely.
Monitoring may include:
Your healthcare provider may stop Ampyra if it does not provide a useful improvement or if the risks become greater than the benefits.
Take one tablet every 12 hours and no more than two tablets in 24 hours. Swallow each tablet whole and never crush, chew, split, or dissolve it.
Skip missed doses rather than replacing them. Contact your healthcare provider if you cannot swallow the tablet, experience a seizure, develop new side effects, or do not notice a meaningful improvement in walking.
Ampyra (Dalfampridine) is available in the following forms and strength:
Ampyra can cause seizures, even in people who have never had one before.
Do not take Ampyra if you have a history of seizures. The risk also increases when too much medication is taken or when doses are taken too close together.
Stop taking Ampyra and seek immediate medical care if a seizure occurs. Ampyra should not be restarted after a seizure.
Take one 10 mg tablet approximately every 12 hours. Do not take more than two tablets within 24 hours.
Taking a higher dose does not provide greater improvement in walking. It can cause dangerously high medication levels and increase the risk of seizures.
If you miss a dose, skip it. Do not take an extra tablet to make up for the missed dose.
The kidneys remove dalfampridine from the body. Reduced kidney function can cause the medication to build up and increase the risk of seizures.
Tell your healthcare provider if you have kidney disease or reduced kidney function. Kidney function should be checked before starting treatment and may need to be monitored regularly.
Ampyra must not be used in people with moderate or severe kidney impairment. People with mild kidney impairment may also have an increased seizure risk and require careful assessment.
Tell your healthcare provider if you are breastfeeding or planning to breastfeed.
It is not known whether dalfampridine passes into human breast milk. Your healthcare provider will consider the benefits of breastfeeding, your need for Ampyra, and any possible risks to the nursing baby before recommending treatment.
Tell your healthcare provider about all prescription medications, over-the-counter products, vitamins, herbal supplements, and compounded medicines you use.
Do not take Ampyra with another product containing dalfampridine, fampridine, or 4-aminopyridine. These products contain the same or a closely related ingredient and may increase the risk of an overdose and seizures.
Do not start, stop, or change another medication without speaking with your healthcare provider.
Ampyra is approved to improve walking in adults with multiple sclerosis, also known as MS. Its benefit was shown through an increase in walking speed. It is not approved to treat other medical conditions. Ampyra also does not cure MS, prevent relapses, or slow the progression of the disease.
The response to Ampyra varies from person to person. Some people may notice an improvement in walking during the first few weeks, while others may receive little or no benefit. Your healthcare provider may assess your walking speed, balance, mobility, and ability to complete daily activities to determine whether the medication is helping. Do not increase the dose if you do not notice an immediate improvement. Higher doses do not provide greater walking benefits and can increase the risk of seizures.
Tell your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. There is limited information about the use of Ampyra during pregnancy and breastfeeding. Your healthcare provider will consider your need for treatment and the possible risks before recommending it. Do not start or stop Ampyra without medical guidance.
If you miss a dose, skip it and take your next tablet at the regular scheduled time. Do not take the missed dose later, take two tablets at once, or take doses closer together. Taking extra medication can increase the amount of dalfampridine in your body and raise the risk of seizures. Continue with your usual schedule and keep approximately 12 hours between doses.
| Generic name: | Dalfampridine |
|---|---|
| Formulation: | Extended Release Tablet |
| Strength(s): | 10mg |
| Quantities Available: | 56, 60, 112, 180 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Ampyra (dalfampridine) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Ampyra is commonly prescribed in a dosage of 10 mg, taken twice daily. For a 90-day supply, this means you would order 180 tablets (90 days x 2 tablets per day).
Yes, we sell dalfampridine. You can enjoy low prices on this medication through our website. To purchase dalfampridine, you will need a valid prescription from your healthcare provider. We require this to dispense the medication. You can mail, fax, or upload your prescription through your online account.
Yes, we ship Ampyra (dalfampridine) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Ampyra (Dalfampridine). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Ampyra (Dalfampridine).
REVIEWS